310 related articles for article (PubMed ID: 30236095)
1. Proteinase 3; a potential target in chronic obstructive pulmonary disease and other chronic inflammatory diseases.
Crisford H; Sapey E; Stockley RA
Respir Res; 2018 Sep; 19(1):180. PubMed ID: 30236095
[TBL] [Abstract][Full Text] [Related]
2. Relevance of the mouse model as a therapeutic approach for neutrophil proteinase 3-associated human diseases.
Korkmaz B; Jenne DE; Gauthier F
Int Immunopharmacol; 2013 Dec; 17(4):1198-205. PubMed ID: 23886601
[TBL] [Abstract][Full Text] [Related]
3. Proteinase 3 activity in sputum from subjects with alpha-1-antitrypsin deficiency and COPD.
Sinden NJ; Stockley RA
Eur Respir J; 2013 May; 41(5):1042-50. PubMed ID: 22936713
[TBL] [Abstract][Full Text] [Related]
4. N-Arylacyl O-sulfonated aminoglycosides as novel inhibitors of human neutrophil elastase, cathepsin G and proteinase 3.
Craciun I; Fenner AM; Kerns RJ
Glycobiology; 2016 Jul; 26(7):701-709. PubMed ID: 26850997
[TBL] [Abstract][Full Text] [Related]
5. Progranulin is a substrate for neutrophil-elastase and proteinase-3 in the airway and its concentration correlates with mediators of airway inflammation in COPD.
Ungurs MJ; Sinden NJ; Stockley RA
Am J Physiol Lung Cell Mol Physiol; 2014 Jan; 306(1):L80-7. PubMed ID: 24186875
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors and Antibody Fragments as Potential Anti-Inflammatory Therapeutics Targeting Neutrophil Proteinase 3 in Human Disease.
Korkmaz B; Lesner A; Guarino C; Wysocka M; Kellenberger C; Watier H; Specks U; Gauthier F; Jenne DE
Pharmacol Rev; 2016 Jul; 68(3):603-30. PubMed ID: 27329045
[TBL] [Abstract][Full Text] [Related]
7. SLPI and trappin-2 as therapeutic agents to target airway serine proteases in inflammatory lung diseases: current and future directions.
Zani ML; Tanga A; Saidi A; Serrano H; Dallet-Choisy S; Baranger K; Moreau T
Biochem Soc Trans; 2011 Oct; 39(5):1441-6. PubMed ID: 21936830
[TBL] [Abstract][Full Text] [Related]
8. α-1-antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease.
Sinden NJ; Baker MJ; Smith DJ; Kreft JU; Dafforn TR; Stockley RA
Am J Physiol Lung Cell Mol Physiol; 2015 Jan; 308(2):L179-90. PubMed ID: 25416382
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
Hwang TL; Wang WH; Wang TY; Yu HP; Hsieh PW
Bioorg Med Chem; 2015 Mar; 23(5):1123-34. PubMed ID: 25650311
[TBL] [Abstract][Full Text] [Related]
10. New selective peptidyl di(chlorophenyl) phosphonate esters for visualizing and blocking neutrophil proteinase 3 in human diseases.
Guarino C; Legowska M; Epinette C; Kellenberger C; Dallet-Choisy S; Sieńczyk M; Gabant G; Cadene M; Zoidakis J; Vlahou A; Wysocka M; Marchand-Adam S; Jenne DE; Lesner A; Gauthier F; Korkmaz B
J Biol Chem; 2014 Nov; 289(46):31777-31791. PubMed ID: 25288799
[TBL] [Abstract][Full Text] [Related]
11. A selective reversible azapeptide inhibitor of human neutrophil proteinase 3 derived from a high affinity FRET substrate.
Epinette C; Croix C; Jaquillard L; Marchand-Adam S; Kellenberger C; Lalmanach G; Cadene M; Viaud-Massuard MC; Gauthier F; Korkmaz B
Biochem Pharmacol; 2012 Mar; 83(6):788-96. PubMed ID: 22209715
[TBL] [Abstract][Full Text] [Related]
12. Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease.
Owen CA
Int J Chron Obstruct Pulmon Dis; 2008; 3(2):253-68. PubMed ID: 18686734
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibitors of human neutrophil proteinase 3.
Korkmaz B; Kellenberger C; Viaud-Massuard MC; Gauthier F
Curr Pharm Des; 2013; 19(6):966-76. PubMed ID: 23016687
[TBL] [Abstract][Full Text] [Related]
14. Lung tissue destruction by proteinase 3 and cathepsin G mediated elastin degradation is elevated in chronic obstructive pulmonary disease.
Gudmann NS; Manon-Jensen T; Sand JMB; Diefenbach C; Sun S; Danielsen A; Karsdal MA; Leeming DJ
Biochem Biophys Res Commun; 2018 Sep; 503(3):1284-1290. PubMed ID: 30017196
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium.
Hiemstra PS; van Wetering S; Stolk J
Eur Respir J; 1998 Nov; 12(5):1200-8. PubMed ID: 9864022
[TBL] [Abstract][Full Text] [Related]
16. Chronic obstructive pulmonary disease: histopathology, inflammation and potential therapies.
Molfino NA; Jeffery PK
Pulm Pharmacol Ther; 2007; 20(5):462-72. PubMed ID: 16798034
[TBL] [Abstract][Full Text] [Related]
17. Reversible ketomethylene-based inhibitors of human neutrophil proteinase 3.
Budnjo A; Narawane S; Grauffel C; Schillinger AS; Fossen T; Reuter N; Haug BE
J Med Chem; 2014 Nov; 57(22):9396-408. PubMed ID: 25365140
[TBL] [Abstract][Full Text] [Related]
18. Neutral serine proteases of neutrophils.
Kettritz R
Immunol Rev; 2016 Sep; 273(1):232-48. PubMed ID: 27558338
[TBL] [Abstract][Full Text] [Related]
19. The Role of Neutrophil Elastase Inhibitors in Lung Diseases.
Polverino E; Rosales-Mayor E; Dale GE; Dembowsky K; Torres A
Chest; 2017 Aug; 152(2):249-262. PubMed ID: 28442313
[TBL] [Abstract][Full Text] [Related]
20. Human proteinase 3 resistance to inhibition extends to alpha-2 macroglobulin.
N'Guessan K; Grzywa R; Seren S; Gabant G; Juliano MA; Moniatte M; van Dorsselaer A; Bieth JG; Kellenberger C; Gauthier F; Wysocka M; Lesner A; Sienczyk M; Cadene M; Korkmaz B
FEBS J; 2020 Sep; 287(18):4068-4081. PubMed ID: 31995266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
